Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
68 hedge funds and large institutions have $11M invested in Carisma Therapeutics in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 17 closing their positions.
7% more call options, than puts
Call options by funds: $892K | Put options by funds: $836K
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
0.07% less ownership
Funds ownership: 0.71% → 0.64% (-0.07%)
7% less funds holding
Funds holding: 73 → 68 (-5)
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
52% less capital invested
Capital invested by funds: $23.1M → $11M (-$12.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$301K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$128K |
| 3 |
CL
CSS LLC
Chicago,
Illinois
|
+$112K |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$97.2K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$88.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$997K |
| 2 |
E
Ergoteles
New York
|
-$802K |
| 3 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
-$269K |
| 4 |
Goldman Sachs
New York
|
-$211K |
| 5 |
Morgan Stanley
New York
|
-$189K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SG
76
StoneX Group
New York
| – | -$12.1K | -745 | Closed |
|
|
PCM
77
Prelude Capital Management
New York
| – | -$9K | -532 | Closed |
|
78
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$2K | -150 | Closed |
|
79
New York State Common Retirement Fund
Albany,
New York
| – | -$1K | -90 | Closed |
|
80
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$831 | -61 | -55% |
|
|
SWM
81
Spire Wealth Management
Mclean,
Virginia
| – | -$1K | -50 | Closed |
|
82
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$531 | +39 | +260% |
|
CARM Hedge Fund Activity: Q3 2022 in Review
68 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q3 2022, worth a combined $11M — down 52% from $23.1M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CARM and 12 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 13 added.
The largest buyer was Renaissance Technologies, adding an estimated $301K. The largest seller was Millennium Management, cutting an estimated $997K.
- 68 institutional investors held Carisma Therapeutics (CARM) as of Q3 2022, down from 73 in Q2 2022.
- Funds reported $11M of Carisma Therapeutics stock for Q3 2022, down 52% quarter-over-quarter.
- 12 funds opened new Carisma Therapeutics positions in Q3 2022 and 17 closed out, a net change of -5 holders.
- The largest Carisma Therapeutics buyer in Q3 2022 was Renaissance Technologies, an estimated $301K added.
- The largest Carisma Therapeutics seller in Q3 2022 was Millennium Management, an estimated $997K sold.
Based on aggregated 13F filings for Q3 2022.